Abstract
Objectives: To evaluate the role of cytoreductive radiofrequency ablation ( cRFA ) in patients with metastatic renal cell carcinoma ( RCC ) with small primary tumours treated with immuno‐ or targeted therapy. To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours. Patients and Methods: Three parallel single‐arm prospective studies were conducted. Eligibility criteria were nearly identical for all trials and included: histopathologically confirmed RCC ; metastatic measurable disease; size of primary tumour P < 0.01 all differences); no differences were found between studies 2 and 3 (objective response rate, P = 0.1; PFS, P = 0.6). Study 1 met its primary endpoint, showing that PFS was significantly longer than the expected 5 months ( P = 0.02). The median (95% CI) overall survival (OS) times were greater in study 2 ( cRFA /sunitinib) and study 3 (sunitinib‐alone) than in study 1 (IFN‐α) at 27.2 (22.6, 31.8) and 22.5 (20.7, 24.3) vs 19.5 (16.3, 22.7) months, respectively. Differences were significant (study 1 vs 2, hazard ratio [HR] = 0.55; P = 0.003; study 1 vs study 3 HR = 0.6, P = 0.01). OS was significantly longer in the cRFA /sunitinib group compared with the sunitinib‐alone group (HR = 0.71; P = 0.04). There were no unexpected toxicities of medical treatment or complications of cRFA . Conclusions: cRFA is a safe and effective approach for select patients with metastatic RCC treated with immunotherapy. The cRFA technique did not improve PFS in patients treated with sunitinib; cRFA probably has impact on OS in these patients. This needs to be tested in a larger trial. Sunitinib was effective in patients with metastatic RCC with unresected small primary tumours.

This publication has 20 references indexed in Scilit: